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Abstract: Prostate cancer is the second leading cause of cancer-related
death in men in most Western countries. In this report, we present 2
cases of metastatic castration-resistant prostate cancer and chronic
kidney disease. Both patients underwent and developed clinical resist-
ance to androgen-deprivation therapy. Subsequently, the patients were
treated with the conventional chemotherapeutic approach, which
resulted in the worsening of renal function and performance status.
Therefore, we opted for treatment with abiraterone acetate, and the
patients exhibited improvements in renal function with good response of
the disease.
(Medicine 93(27):e163)
Abbreviations: AA = abiraterone acetate, CKD = chronic kidney
disease, FDA = Food and Drug Administration, mCRPC =
metastatic castration-resistant prostate cancer, PSA = prostate-
specific antigen, WBC = white blood cell count.
INTRODUCTION
A biraterone acetate (AA) is a novel irreversible inhibitor ofCYP17 that was approved by the Food and Drug Admin-
istration (FDA) on April 28, 2011 in combination with pre-
dnisone for the treatment of metastatic castration-resistant
prostate cancer (mCRPC), which was previously treated with
docetaxel. The approval of this agent was based on a multi-
national randomized, double-blind, placebo-controlled, phase
III trial that involved 1195 patients with docetaxel-refractory
CRPC.1 This study demonstrated a median overall survival in
the AA arm of 14.8 months compared with 10.9 months in the
placebo arm (hazard ratio: 0.646, 95% confidence interval:
0.54–0.77; P¼ 0.0001). Furthermore, in 2013, AA was
approved by regulatory agencies in the United States andIda Fiaschi, Phar aera, MD, and
oviello, MD
who were treated with AA/prednisone exhibited prolonged
overall survival compared with those treated with a regimen
of placebo/prednisone.2 More recently, the prespecified interim
analysis of the efficacy and safety outcomes in the COU-AA-
302 study revealed median overall survivals of 35.3 months on
AA versus 30.1 months on placebo.3
Within the histories of patients with prostate cancer, the
development of a chronic kidney disease (CKD) is not uncom-
mon. In this report, we describe 2 patients with mCRPC and
CKDwho were treated with AA and experienced improvements
in renal function, dramatic declines in prostate-specific antigen
(PSA) levels, improvements in performance status, and
reductions in bone pain.
CASE REPORT 1
In 2002, a 76-year-old man presented with a PSA level of
15 ng/mL. His physical examination was normal, and a digital
rectal examination revealed a slightly enlarged prostate. Biop-
sies revealed a prostate cancer with no evidence of distant
metastases and a Gleason score of 7 (4þ 3). Given the patient’s
advanced age, surgery was excluded. Moreover, the patient
refused to undergo radiotherapy; therefore, he was treated with
leuprolide and oral bicalutamide.
Follow-up visits were scheduled every 3 months that
included serial physical examination, routine blood evaluations
that included serum PSA determinations at regular intervals
(every 2–3 months) and radiological assessments every 6 to 12
months or as clinically indicated.
In January 2010, an episode of hematuria, urinary reten-
tion, and bilateral hydronephrosis with acute renal failure
(creatinine 6.39mg/dL) occurred, and a percutaneous ureter-
ostomy was performed. However, although the episode of acute
kidney failure was resolved, the patient presented with CKD in
subsequent tests (creatinine 2.0mg/dL, creatinine clearance
35mL/min). Stage 3B CKD was diagnosed and required obser-
vation and control of blood pressure and other risk factors.
In May 2010, the patient reported low-grade, constant back
pain. A radionuclide scintigraphy revealed several areas sug-
gestive of metastatic bone disease (ie, the right parietal bone,
lumbar spine, sternum, ribs, pelvis, and right femur), and a
serum PSA determination revealed a level of 210 ng/mL.
Therefore, the patient began chemotherapy with estramus-
tine phosphate 560mg per os daily and zoledronic acid intra-
venously every 28 days. Laboratory data revealed the following
values: haemoglobin level 11.8 g/mL, hematocrit 38.5%,
white blood cell count (WBC) 4200 cells/mm3, platelets
179,000 cells/mL, blood urea nitrogen 69mg/dL, creatinineinine clearance 26.92mL/min (stage
of the patient, the normality of the
ow urea value, renal replacement was
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his PSA level is 0.1 ng/mL (24 months without an increase in
PSA), his creatinine is 1.6mg/dL, and his creatinine clearance is
38.16mL/min (stage 3B CKD).not considered. Abdomen CT revealed the presence of a
bilateral percutaneous ureterostomy with reduction of both
kidneys, particularly the left, and the CT also revealed the
presence of multiple osteosclerotic lesions in the lumbar spine
and pelvis.
Follow-up visits that included determination of the
serum PSA were scheduled every 2 months. These evaluations
revealed a progressive increase in PSA to 421 ng/mL (Figure 1);
therefore, in July 2011, the patient received a second line of
chemotherapy with docetaxel 40mg/m2 intravenous infusion on
days 1, 8, 15, 22, and 29 in a 6-week cycle.
Over the first 3 months, the PSA exhibited a small decrease
to 339.7 ng/mL; after 6 months of treatment, the PSA went
down to 243.7 ng/mL, but the laboratory data revealed a wor-
sening of renal function with a blood urea nitrogen level of
60mg/dL, a creatinine level of 3.5mg/dL, and a creatinine
clearance of 19.64mL/min (stage 4 CKD). Furthermore, the
patient reported a partial resolution of the back pain. In contrast,
the patient experienced considerable toxicity with side effects
including neutropenia, anemia, thrombocytopenia, fatigue, nail
changes, dry eyes, which were grades I or II in most of the
examinations, and a worsening of performance status. Treat-
ment with docetaxel was discontinued, and, due to the toxicity, a
hormonal approach with oral AA was undertaken (1000mg die,
administered as four 250-mg tablets and prednisone 10mg die
in 2 daily dosings).
Six months after beginning the new treatment, the PSA
exhibited a substantial reduction (48.57 ng/mL; Figure 1), an
improvement in renal function was observed (blood urea nitro-
gen 45mg/dL, creatinine 2.1mg/dL, and creatinine clearance
32.14mL/min [stage 3B CKD]), electrolytes were normal, and
the patient reported a reduction in bone pain with a decrease in
analgesic consumption and an improvement in performance
status. The treatment was well-tolerated without considerable
side effects.
Currently, the patient is continuing treatment, his
PSA level is 24.5 ng/mL (28 months without an increase in
PSA), his creatinine is 2mg/dL, and his creatinine clearance is
33.13mL/min (stage 3B CKD).
CASE REPORT 2
In November 2004, a 59-year-old man presented with a
PSA of 13.7 ng/mL and a Gleason 7 (3þ 4) prostate adeno-
Francini et alcarcinoma. He underwent radical prostatectomy, and extensive
perineural invasion and an extracapsular extension of the tumor
were found. Subsequently, he was treated with radiation therapy
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FIGURE 1. Trend of creatinine clearance and PSA during doce-
taxel and abiraterone acetate therapy.
2 | www.md-journal.comand androgen-deprivation therapy consisting of leuprolide and
oral bicalutamide.
Follow-up visits were scheduled every 3 months with
serial physical examinations, routine blood evaluations, which
included serum PSA determinations at regular intervals
(every 2 to 3 months), and radiological assessments every 6
to 12 months or as clinically indicated.
In October 2009, his PSA increased to 53.45 ng/mL, and an
abdominal magnetic resonance imaging identified metastases to
the pelvic lymph nodes. From 2010 through 2011, the patient
received docetaxel and epirubicin (11 cycles) followed by
weekly navelbine per os for 6 months. In November 2011,
there was a substantial increase in the PSA value (72.68 ng/mL;
Figure 2), and the patient underwent docetaxel rechallenge with
weekly docetaxel alone for 4 months.
During the first cycle of docetaxel rechallenge, an episode
of urinary retention and bilateral hydronephrosis with acute
renal failure (creatinine 7.34mg/dL) occurred, and a percuta-
neous ureterostomy was performed. When the episode of acute
kidney failure was resolved, laboratory tests revealed CDKwith
a creatinine level of 2.6md/dL and a creatinine clearance of
24.62mL/min. A stage 4 CDK was diagnosed and required
observation and control of blood pressure and other risk factors.
Other options were not considerate due to the age of the patient
and the normality of the electrolytes and urea.
In March 2012, the PSA value decreased to 29.78 ng/mL;
however, laboratory data revealed a partial improvement in
renal function with a blood urea nitrogen level of 83mg/dL, a
creatinine level of 3.1mg/dL, and a creatinine clearance of
20.32mL/min (stage 4 CDK). Moreover, the patient began to
suffer from the side effects of chemotherapy; therefore, some
cycles were delayed due to toxicity.
Subsequently, he began AA (1000mg die, administered as
four 250-mg tablets and prednisone 10mg die in 2 daily dosing).
His PSA exhibited a substantial reduction (4.91 ng/mL;
Figure 2), improvements in renal function were observed (blood
urea nitrogen 57mg/dL, creatinine 1.7mg/dL, creatinine clear-
ance 37.06mL/min, stage 3B CKD), his electrolyte levels were
normal, and the treatment was well tolerated without consider-
able side effects. Currently, the patient is continuing treatment,
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FIGURE 2. Trend of creatinine clearance and PSA during doce-
taxel and abiraterone acetate therapy.
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neDISCUSSION
Until recently, patients who had progressed following
docetaxel treatment had very limited options that included
mitoxantrone, which was the first cytotoxic agent to be
approved for the palliative treatment of men with CRPC.4 Other
agents have been tested, but most studies have reported no
objective responses or responses of <15%,5 and unfortunately,
all of these agents have provided short-term clinical responses
that are associated with a considerable toxicities. Moreover, the
antifungal agent ketoconazole, which is used as an inhibitor of
the activities of several enzymes involved in androgen synthesis
such as CYP17 and CYP11, has been investigated.6 However,
ketoconazole lacks specificity for the CYP17 family of
enzymes, which unfortunately leads to significant toxicities
(eg, hepatotoxicity, gastrointestinal toxicity, and adrenal insuf-
ficiency).6
In the past 3 years, several new agents with different
mechanisms of action have been developed for the treatment
of prostate cancer1,2,7,9–12 with the goal of prolonging the
overall survival of CRPC patients. Sipuleucel-T has been found
to improve the overall survival of asymptomatic or mildly
symptomatic men, most of whom had not received chemother-
apy.7 However, sipuleucel-T has primarily been used in the
United States and has been used less in Europe.8 Cabazitaxel
was approved by the FDA for the treatment of patients with
mCRPC who have previously been treated with docetaxel
chemotherapy.9
Unfortunately, treatment with cabazitaxel is not without
toxicity; indeed, severe neutropenia is common (89%), and 18%
of patients discontinue the drug due to adverse events.9 Radium-
223 has been reported to have a favorable safety profile with
minimal myelotoxicity10; nevertheless, reports on the efficacy
of radium-223 are recent, and at the time of this report, radium-
223 was not commercially available. Rather, based on a
systemic hormonal approach, AA and enzalutamide were
approved for the treatment of patients with mCRPC following
docetaxel treatment.1,2–11 Although enzalutamide exhibits a
favorable toxicity profile,11,12 it could not be used for our
patients because it is not yet commercially available; therefore,
we opted for treatment with AA and excluded further lines of
chemotherapy with cabazitaxel.
Since the first phase II studies of AA,13 it has been clear
that the blockade of cytochrome CYP17 is associated with
increased mineralocorticoid levels that result in some adverse
events, the most common of which are hypokalemia, fluid
retention, and hypertension; however, these toxicities are lar-
gely abrogated by the co-administration of low-dose glucocor-
ticoids.
As illustrated by the 2 cases reported herein before, the
patients continued to respond to treatment with docetaxel, but
their laboratory data revealed worsening of their renal function
that prevented the continuation of treatment with this che-
motherapeutic agent. Conversely, after initiating AA, their renal
functions exhibited improvements (Figures 1 and 2) without
significant toxicity. Notably, in our patients, AA exhibited its
efficacy via substantial PSA responses that were sustained over
time. Indeed, after 28 and 24 months, the patient’s PSAs did not
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resistant Prostate Cancerprogression and the overall median survival of patients who
were treated with AA in the trial by de Bono (10.2 and 14.8
# 2014 Lippincott Williams & Wilkinsmonths, respectively). Interestingly, our patients also exhibited
longer times to PSA progression than the median time of the
patients in the COU-AA-302 trial (11.1 months). Therefore, the
prognoses were better for our cases. However, it is difficult to
explain the reasons for the prolonged survivals observed in our
cases and whether the CDK played a role. To date, both patients
are still receiving AA treatment.
CONCLUSIONS
Recent studies showed that systemic hormone therapy is a
well-tolerated option by the patients with CRPC. AA is one of
the emerging novel therapies for advanced prostate cancer that
employs a systemic hormonal approach.
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